Legal Weed Sales Projected To Grow 14% in 2023

Sales of legal cannabis in the United States are projected to grow by 14% in 2023, according to a recent report from Colorado-based cannabis industry market analysis firm BDSA. In an updated five-year global legal cannabis market forecast, the company reports that global spending on legal cannabis increased by 4.8% to $32 billion in 2022. BDSA projects that the global cannabis market will see a compound annual growth rate (CAGR) of 13.2% from 2022 to 2027, resulting in a total worldwide regulated cannabis market size of $59.6 billion by 2027.

The U.S. legal cannabis market has shown significant growth across the industry as more and more states legalize adult-use cannabis and medical marijuana. And while the industry’s growth slowed in 2022 in response to market conditions including rising inflation and economic uncertainty, BDSA expects the U.S. legal weed market to again show significant growth this year, projecting a 14% increase in the market in 2023.

“Legal cannabis spending slowed significantly in 2022 due to rapid price declines across all markets,” Roy Bingham, co-founder and CEO of BDSA, said in a statement from the company. “Despite this, our updated forecast predicts strong growth in the U.S. driven by developing markets, particularly the adult-use markets of Missouri, New Jersey and New York.”

Currently, 21 states have legalized cannabis for adults, while 37 states, the District of Columbia and three U.S. territories have passed laws to legalize the medicinal use of marijuana. Additionally, 11 states permit the use of low-THC cannabis formulations for medicinal purposes. Only Idaho and Nebraska continue to prohibit all forms of cannabis. 

Some Mature Cannabis Markets Contracted In 2022

The U.S. cannabis market posted rapid growth during the height of the COVID-19 pandemic as lockdowns kept consumers home and dispensaries were designated as essential businesses in many states. But last year marked the first decline in overall cannabis spending in some mature cannabis markets in the United States. In the West, early cannabis policy reform adopters California, Colorado, Nevada and Oregon saw a combined drop in spending on legal adult-use cannabis of 16.5% in 2022, according to the updated report. BDSA expects most mature cannabis markets in the U.S. to return to positive growth in 2024, although more slowly through 2027 than in the years leading up to the pandemic. 

Newer legal cannabis markets showed strong growth in 2022, despite the decline seen in more mature markets. BDSA also projects new legal adult-use cannabis markets to launch by 2027, predicting a start of legal sales in Maryland in 2024 and in Florida and Ohio in 2025. The launch of new recreational marijuana cannabis markets is also possible in Minnesota and Hawaii by 2027, BDSA notes, but the company does not expect to see federal cannabis legalization during the five-year forecast period.

Brian Vicente, founding partner of the cannabis law firm Vicente LLP, agreed that emerging markets will help fuel the growth of the legal cannabis industry in the upcoming years.

 “The future remains bright for the cannabis industry in the United States. Despite a recent setback at the polls, with Oklahoma voters shooting down legalization this month, we are still seeing other domestic markets expand and commence sales,” Vicente wrote in an email. “This includes significant revenue growth in newly-legal cannabis markets like Missouri and New Jersey, and also emerging medical markets like Mississippi. With additional states like Florida and Ohio looking likely to legalize in the next several years, we can expect continued expansion in cannabis sales.”

By 2027, U.S. sales of adult-use cannabis are forecasted to contribute 78% of the total spending on legal cannabis worldwide, up from 64% in 2022. U.S. legal cannabis spending is expected to grow at a CAGR of 11.3%, from $26.1 billion in 2022 to $44.5 billion in 2027, with the industry’s growth driven primarily by the New York, Florida, New Jersey and California recreational marijuana markets. 

Globally, cannabis markets outside the U.S. and Canada are forecast to grow at a CAGR of 40% to $9.5 billion in 2027, up from $1.8 billion in 2022. BDSA forecasts the Canadian market will see overall growth of 12% this year, increasing to a $5.7 billion market by 2027 at a CAGR of 6.3%. New adult-use markets in Germany and Mexico are expected to be the primary drivers of global growth, while existing limited medical cannabis programs are expected to expand, particularly in the European Union and Latin America.

The post Legal Weed Sales Projected To Grow 14% in 2023 appeared first on High Times.

Justice Department Launches Expungement Application

The time is now to expedite the process and get proof of pardon for low-level federal cannabis convictions that no longer stand today yet still haunt individuals, sometimes decades later. According to a March 3 announcement, the U.S. Department of Justice is launching the application to make the expungement process easier for people with low-level federal cannabis convictions. 

For people who are interested, you’ll need to gather personal details like name, mailing address, email address, and citizenship status. You’ll also need to know the docket or case number and the code section that was charged, and provide copies of documentation, such as charging documents (indictment, complaint, or criminal information) or conviction documents. It’s also important to know the exact date the sentence was imposed.

Pardons for low-level cannabis convictions were promised by President Joe Biden last October.

“Today, the Justice Department is launching an application for eligible individuals to receive certificate of proof that they were pardoned under the Oct. 6, 2022, proclamation by President Biden,” the department wrote on March 3. 

“On Oct. 6, 2022, the President announced a full, unconditional and categorical pardon for prior federal and D.C. offenses of simple possession of marijuana. The President’s pardon lifts barriers to housing, employment and educational opportunities for thousands of people with those prior convictions. President Biden directed the Justice Department to develop a process for individuals to receive their certificate of pardon.”

The Application for Certificate of Pardon will be available on the Office of the Pardon Attorney’s website. People with eligible cases may submit documentation to the Office of the Pardon Attorney and receive a certificate indicating the person was pardoned on Oct. 6, 2022, for simple possession of cannabis.

The President’s pardon can assist pardoned cases by removing civil or legal penalties such as restrictions on the right to vote, to hold office, or to sit on a jury.

The process makes getting proof of pardon quite a bit easier for people seeking to obtain licenses, bonds, or employment. President Biden said last October that the point of pardoning low-level cannabis convictions is to “help relieve the consequences arising from these convictions.” 

In order to be eligible for a certificate, an applicant must have been charged or convicted of simple possession of cannabis in either a federal court or D.C. Superior Court, and the applicant must have legally resided the United States at the time of the offense. In addition, an individual must have been a U.S. citizen or lawful permanent resident on Oct. 6, 2022.

Those who were convicted of state-level cannabis offenses do not qualify for the pardon.

In a historic move on October 6, 2022, Biden announced that he will pardon people with federal convictions for simple possession of cannabis, and announced that he will direct the U.S. Attorney General Merrick B. Garland and Secretary of the Department of Health and Human Services Xavier Becerra to begin the process of reviewing the classification of cannabis at the federal level.

The White House statement noted that under current federal law, cannabis falls under Schedule I alongside deadly drugs like fentanyl. The White House will  “review expeditiously” the plant’s current classification.

“As I’ve said before, no one should be in jail just for using or possessing marijuana,” Biden tweeted. “Today, I’m taking steps to end our failed approach. Allow me to lay them out.”

For more information about determining eligibility and to find answers to frequently asked questions, visit Presidential Proclamation on Marijuana Possession.

The post Justice Department Launches Expungement Application appeared first on High Times.

Twitter To Allow THC, CBD, and Related Ads in U.S.

In a seismic shift away from the way nearly all major social media platforms handle cannabis ad-related content, Twitter announced it will be the first to allow cannabis-related ads based in the U.S. 

Twitter announced that it will allow advertisers to promote branded and informational cannabis-related content under the following categories: CBD and similar cannabinoid products; THC and similar products; as well as cannabis-related products and services such as delivery services, labs, growing technology, search engines, and events.

The cannabis ad policy move changes everything for businesses with the money to advertise. Toronto, Ontario-based AdCann in Canada was the first to break the news.

“Up until now, only CBD topical brands were permitted to advertise on Twitter’s platform,” AdCann wrote on its website. “Moving forward—the social network will allow for the promotion of regulated THC and CBD-containing cannabis products, accessories, services and more.” 

AdCann continued, “American cannabis companies, brands, and purveyors will need to pass through a Twitter advertiser approval process to ensure they are legitimate and educated on the platform. Once approved, industry marketers will have access to Twitter’s entire suite of advertising products including promoted tweets, promoted product opportunities, location-specific takeovers, in-stream video sponsorships and partner publication features.”

AdCann reiterated that in Canada, cannabis has been legal at the federal level since 2018, so Twitter already allows for cannabis advertising in the country.

Cannabis Companies React to Policy Change

Leading cannabis company PAX, makers of industry standard devices like the PAX Pro and PAX Era, is among the first brands to advertise cannabis-related content on Twitter. 

“This is a big moment, as a major advertising platform is making the decision to treat cannabis like any other consumer products category,” Luke Droulez, VP of Marketing at PAX said in a statement obtained by High Times. “We’re excited to be among the first of Twitter’s cannabis advertising partners and be able to engage customers more directly. After decades of prohibitionist propaganda, there is an opportunity to destigmatize and normalize the plant and its use.”

Twitter posted the policy update on its Drugs and Drug Paraphernalia section of the website, which outlines the process for advertisers promoting cannabis products.

“We permit approved cannabis (including CBD – cannabinoids) advertisers to target the United States, subject to the following restrictions:

  • Advertisers must be licensed by the appropriate authorities, and pre-authorized by Twitter.
  • Advertisers may only target jurisdictions in which they are licensed to promote these products or services online.
  • Advertisers may not promote or offer the sale of cannabis (including CBD – cannabinoids)
    • Exception: Ads for topical (non-ingestible) hemp-derived CBD topical products containing equal to or less than the 0.3% THC government-set threshold.       
  • Advertisers are responsible for complying with all applicable laws, rules, regulations, and advertising guidelines.
  • Advertisers may not target customers under the age of 21.”

Elon Musk and the New Twitter

Twitter owner and billionaire Elon Musk is in an ongoing game of chess: It’s the latest major change on the platform under his watch, among many, including the decisions to launch paid verification and reinstate accounts like Donald Trump’s.  

Meanwhile, on Feb. 4, Twitter owner Elon Musk cryptically tweeted “420,” which assuredly is a jab back at a previous 2018 tweet about 420 that landed him in trouble with government and aerospace officials.

In 2018, Musk rounded up Tesla shares from $419 to $420, announcing his plan to go private in a tweet. “Am considering taking Tesla private at $420,” Musk tweeted on Aug. 7, 2018. “Funding secured.”—sending officials from The Securities and Exchange Commission (SEC) into a tailspin. Musk denied the tweet was about cannabis in a California court.

The post Twitter To Allow THC, CBD, and Related Ads in U.S. appeared first on High Times.

Navigating Your Way Through Cannabis and DUI Laws

It can be pretty difficult navigating cannabis DUI and laws in Canada and the US. Thankfully, there are some useful resources we can refer to. Laws around driving high tends to vary a lot. In Canada and the United States, it really depends on which province or state you live in. Thankfully, the United States […]

The post Navigating Your Way Through Cannabis and DUI Laws appeared first on Cannabis News, Lifestyle – Headlines, Videos & Cooking.

US Cannabis Market Trends

What are the trends in the US cannabis market? Each state has its own laws and regulations concerning cannabis. But at this point, cannabis legalization in the United States seems like an inevitable possibility. So in the meantime, we can look to the legal States and discern some direction. Overall, US cannabis markets have matured […]

The post US Cannabis Market Trends appeared first on Cannabis News, Lifestyle – Headlines, Videos & Cooking.

War and Peace and Cannabis

Since it is almost always the poor sent to fight wars, the political left has correctly used the metaphor of pawns in a larger, murderous chess game. This tide started to turn under Obama. His 2008 campaign is a testament to how the left used to be antiwar. But once he became president, not only […]

The post War and Peace and Cannabis appeared first on Cannabis News, Lifestyle – Headlines, Videos & Cooking.

Inequality in the Cannabis Industry and the Push for Social Equity

Inequality in the cannabis industry exists, and some companies have tried to address this by pushing for social equity. Currently, representation in the cannabis industry is extremely uneven. A survey found that American cannabis companies were disproportionality White. According to the survey, about 87% of company owners are White, and other minority groups each made […]

The post Inequality in the Cannabis Industry and the Push for Social Equity appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.

2021 Roundup of Cannabis Reform in Europe (and 2022 Predictions)

As the world contemplates a whole new year, whether or not COVID will finally recede, there are a few things to cheer about, including cannabis reform. Namely, no matter how many uncertainties face us all, as grey January stretches beyond the holiday lights, there is certainly cheer in the air that will last much longer than the season.

Indeed, there are plenty in Germany right now who are already making plans for infused Weihnacht treats just a few years hence. It is now clear that cannabis will take its place quickly in German traditions, Christmas being just one of them. Canna-Glüwein (hot, mulled wine), anyone?

Beyond this, the rest of the EU now teetering on the edge on this issue, has now woken up to the reality that no matter what they decide to do (Portugal, Spain, Italy, Greece, Malta and, of course, the current laggard, France), now that Germany has just uttered the declaration that is the beginning of the end. If not an inevitable form of economic development and tax money in a world starved of the same.

Cannabis has turned a major corner in Europe in 2021. Here are the major hallmarks of the year.

Red, Amber, Green, Go Deutschland!

Germany’s new “Traffic Light” political coalition has promised to address the issue of recreational reform legislatively in 2022. Unlike the U.S. where multiple attempts to pass federal cannabis reform have failed, this is likely to happen. 

In the initial rollout of reform, however, do not be surprised if the Germans decide to follow the Swiss and allow regular pharmacies to be the first port of call for both medical and recreational users. It would solve several issues at once—starting with the establishment of tight restrictions on cultivation and retail supply chain. 

A short term, interim solution such as this will knock out a far more contentious issue—how to structure a licensing system for everything from cultivation in the country (and by whom) to specialty shops that resemble American or Canadian “dispensaries.” Namely not medical establishments. Plus, online sales.

This is for both Germany and cannabis reform, expect there to be several iterations of reform, starting with state and city experiments that will inevitably see Berlin, Bremen, Dortmund, Frankfurt, Dusseldorf, Cologne and Munich on the front lines (because such ideas have been avidly pushed on a municipal level before).  

Also, don’t forget that it basically took four years after the law changed and two after the cultivation bid was finally awarded, for there to be distribution of German cultivated medical cannabis. Don’t expect the details of recreational to be handled or hammered out much more quickly. See Canada.

In the meantime, however, full decrim will become the law of the land, and patients will be free of prosecution, both for possession and presumably (hopefully) reasonable home growing. Despite the reluctance to actually have cannabis cultivated in the country, either by patients or companies (see the drama over the first cultivation bid), this is not 2017. Germans, albeit grudgingly, now admit that the drug does work, as a drug, even if they are not yet of one voice in the majority that cannabis prohibition has of course, failed.

Regardless, German recreational, just as medical reform was before it, is a huge, huge step which will drive other countries across the region forward too.

Malta and Luxembourg will Lead the Way

It is a sign of how convoluted the Dutch situation is, if not national position, generally, that the island of Malta led the way on actual, formal, federal, recreational cannabis reform within the European Union (EU). Indeed, if there are analogies to be made, Holland is kind of like the European California—creating a market that exists in the grey areas but is only now facing a discussion (and further one far from complete) about how to federally regulate the industry.

Luxembourg also, it appears, was just hanging back until another country took the leap, despite promising the same in 2018 as a new coalition government took the reins there. Now there is no excuse for any more delays.

Portugal will also inevitably now enact reform as soon as the smoke from the general election early next year clears—and no matter who wins. The country needs an economic boost—either from tourism or exports, and this is a natural solution.

Beyond this, Spain may well follow a Dutch model to formalize production for its clubs rather than coffee shops in the next 12 to 24 months.

Also expect to see Austria, Italy, the Czech Republic, Greece and potentially outliers like Belgium begin to move with the herd, even if in the creation of experimental markets. This may or may not start to happen next year, but it will most certainly catch on within the next 24 months.

The Swiss Wild Card

Do not forget, of course, that the Swiss began preparing for a recreational trial rollout that now has a calendar date set for actual lift off in 2022. Companies have been submitting and obtaining approvals for the last eight months or so.

The beginning of this market, with its own strange requirements and rules, will also inevitably drive discussions and the shape of reform just across the DACH if not other EU borders the country shares with other countries. Everyone will be watching what goes down in Der Schweitz—including the unique waiving and blending of certain kinds of certifications—including but not limited to Novel Food and GMP.

Other Notables (or Not)

Try as they might to get some respect, the British cannabis industry, such as it is, has weathered difficult times, and these do not seem at least for now, to be ending any time soon. 

In contrast to the British on both European membership and cannabis reform, North Macedonia will inevitably play a role in the immediate future, even if just as a source of cheaper flower and oil extracts.

Poland is also still teetering on the brink of actual if not accessible medical reform, but expect this now also to speed up.

The Growth of Import Markets Serving Europe

The year 2021 was notable for another reason. Feeder markets will target EU if not Germany at their founder’s mandate, continued to grow. This means that no matter what happens with future cultivation discussions, in any country, starting with Germany, there will be no shortage of other certified cannabis from countries all over the globe at this point, looking for a German home. 

For this reason, there will be significant downward pressure on both the medical and “other” flower and biomass discussions.

Bottom Line On 2021?

If there is an analogy to be made, the situation in Europe now on the ground looks a great deal like the conversation in the U.S. in 2012, post presidential election that returned Obama to his second term in office. Namely, two states, Colorado and Washington State, voted on state mandates to create state markets. They both bloomed in 2014—and the rest, as they say, is history.

The developments this year in Europe, and even some of the stuttering delays, no matter their cause or ultimate resolutions, resemble this period, in many ways. And that spells great news for the industry, on all fronts.

The post 2021 Roundup of Cannabis Reform in Europe (and 2022 Predictions) appeared first on High Times.

Study Shows Psychedelics Users Had Less Stress During Pandemic Lockdowns

A study on the COVID-19 outbreak’s impact on mental health has found that users of psychedelics experienced less stress during the pandemic than those who had not used the drugs. 

Before the pandemic, approximately 8.5 percent of U.S. adults reported being depressed. But as the nation experienced the fear, lockdowns, and isolation associated with the COVID-19 outbreak, the figure spiked to 27.8 percent, according to data published last year. Prof. Sandro Galea, a dean at Boston University School of Public Health, said that the impact on mental health caused by the pandemic is unprecedented.

“Depression in the general population after prior large-scale traumatic events has been observed to, at most, double,” he said after publishing research on mental health aspects of the pandemic last year.

Anxiety levels also increased during the pandemic, with researchers reporting a 14 percent rise in anxiety among residents of the U.S., U.K., Canada, and Australia.

Psychedelics and Depression

Other research has shown that psychedelic drugs including psilocybin have potential as treatments for mental health conditions including depression, anxiety and addiction. To learn if the use of psychedelic drugs affected the impact that the coronavirus pandemic had on mental health, researchers affiliated with organizations in the Netherlands, Spain and Brazil conducted a study of how previous psychedelic use affected mental health. The study was performed from April through July of last year, when much of the world was under lockdown to help stem the spread of the virus.

The researchers conducted an online survey of 2,974 people, with most respondents living in Spain, Brazil and the United States. Among the participants, 497 said they regularly used psychedelic drugs, 606 were occasional users and 1,968 said they had never used psychedelics. During the study period, most of the United States and Spain were under lockdown, although that was not the case in Brazil.

The survey asked participants about their use of psychedelic drugs including psilocybin, peyote, MDMA, ayahuasca, LSD, San Pedro, and 5-MeO-DMT, both before and after the outbreak began, as well as information about the settings in which the drugs were used. Study subjects also completed a series of questionnaires on psychological distress, perceived social support, post-traumatic stress symptoms, psychological status and measures of personality.

“Psychedelic drug users, especially regular ones, reported less psychological distress, less peritraumatic stress, and more social support,” the authors of the study wrote.

Half of the participants who had used psychedelics said that their previous use of the drugs had a significant positive impact on their ability to cope with the stress associated with the lockdowns. About a third (35 percent) said their past use of psychedelic drugs did not impact their ability to cope, and 16 percent said their experience with the compounds had a small beneficial impact.

Psychedelic drug users also reported having more access to outdoor spaces and spending more time outside. Regular users of psychedelics also reported more engagement with activities including music, meditation, yoga and Pilates, while those who do not use psychedelics said they spent more time doing aerobic exercise, playing video games and watching television, movies and news coverage related to the COVID-19 pandemic. 

Regular users were also less likely to follow suggested public health measures such as wearing face masks and gloves. In personality tests, people who reported using psychedelics scored higher on scales for novelty seeking and self-transcendence, and lower for cooperativeness.

Correlation or Causation?

The study also revealed other consequences of the pandemic that could have an impact on mental health. Nearly a fifth of participants reported losing their job, while almost half said their income had declined during the outbreak.

The researchers wrote that although psychedelics users reported experiencing less stress during the pandemic, it is unclear if the drugs are responsible for the difference. They called for continued research, noting that other factors including more access to outdoor space, spending more time outside, healthier eating habits, and spending less time viewing or listening to news coverage about the pandemic could also have an impact on mental health.

“Our findings showed that regular users of psychedelic drugs had less psychological stress and some personality differences when compared to occasional users and non-users,” the study’s authors concluded. “This suggests that either the use of psychedelics might be a protective factor itself or people with certain previous traits are more prone to frequently using psychedelic drugs.”

An article on the research, “Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study,” was published online by the peer-reviewed journal Frontiers in Psychiatry.

The post Study Shows Psychedelics Users Had Less Stress During Pandemic Lockdowns appeared first on High Times.

U.S. Reports More Than 100,000 Overdose Deaths In One Year

More than 100,000 people succumbed to overdose deaths in the United States in the span of a year, a record death toll that underscores the continuing failure of the War on Drugs to keep the nation safe.

During the 12-month period ending April 2021, 100,306 Americans died of drug overdoses, according to provisional data released by the U.S. Centers for Disease Control and Prevention on Wednesday. Federal officials point to the coronavirus pandemic and the proliferation of powerful synthetic opioids including fentanyl as major contributors to the spike in overdose deaths over the past two years.

“These are numbers we have never seen before,” Dr. Nora Volkow, director of the National Institute on Drug Abuse, told the New York Times. Commenting on the human toll behind the statistics, Volkow noted that a majority of the deaths occurred among people aged 25 to 55.

“They leave behind friends, family and children, if they have children, so there are a lot of downstream consequences,” Dr. Volkow said. “This is a major challenge to our society.”

Overdose Deaths Add to Covid-19’s Toll

During the same time period, approximately 509,000 died from Covid-19 in the United States, according to figures from Johns Hopkins University, while millions were left isolated due to quarantines and business closures. Volkow noted that the pandemic also led to border shutdowns that made powerful synthetic opioids including fentanyl easier to smuggle into the country than naturally produced but less potent and thus more bulky drugs including morphine and heroin.

“What we’re seeing are the effects of these patterns of crisis and the appearance of more dangerous drugs at much lower prices,” Volkow said to CNN. “In a crisis of this magnitude, those already taking drugs may take higher amounts and those in recovery may relapse. It’s a phenomenon we’ve seen and perhaps could have predicted.”

The new data, representing deaths from May 2020 through April 2021, reflects a 28.5 percent increase in the number of fatal overdoses in the United States compared to the same time period one year earlier and the first time deaths have exceeded 100,000 in one year. Synthetic opioids including fentanyl were up 49 percent over the year before, contributing to the vast majority (64 percent) of overdose deaths. Stimulants including methamphetamines were involved in about a quarter of overdose deaths, a jump of 48 percent over the previous year. The data also show more modest increases in the number of overdose deaths caused by natural opioids, cocaine and prescription medications.

Dr. Volkow said that while some drug users intentionally seek out fentanyl, others “may not have wanted to take it. But that is what is being sold, and the risk of overdose is very high.”

The pandemic also decreased the availability and access to treatment for substance use disorders. As the country reopens and life begins to return to normal, overdose deaths are likely to remain high if access to drug treatment and other interventions is not improved, experts says.

“Even if Covid went away tomorrow, we’d still have a problem. What will have an impact is dramatic improvement to access to treatment,” said Dr. Andrew Kolodny, medical director of opioid policy research at the Brandeis University Heller School for Social Policy and Management.

“These are deaths in people with a preventable, treatable condition. The United States continues to fail on both fronts, both on preventing opioid addiction and treating addiction,” he continued, adding that President Joe Biden should act on his campaign promises to address the continuing opioid crisis.

Access to Treatment Saves Lives

The White House Office of National Drug Control Policy on Wednesday released model legislation to serve as a guideline for states to pass laws that increase access to naloxone, a life-saving drug that can reverse opioid overdoses. Other medications including buprenorphine can be prescribed to help those with opioid use disorder, but access to the drugs is also often limited. In October, the U.S. Department of Health and Human Services issued a plan to combat drug overdoses, including federal support for harm reduction and recovery services and provisions that lessen barriers to substance abuse treatment.

“If we really want to turn the corner, we have to get to a point where treatment for opioid addiction is easier to access than fentanyl, heroin, or prescription opioids are,” Kolodny said.

Beth Connolly, director of the Pew Charitable Trusts substance use prevention and treatment initiative, said that improving access to drug treatment and emergency interventions can help bring down the spike in overdose deaths.

“The evidence is really clear that using medications to treat opioid addiction disorders saves lives,” said Connolly. “As we see more and more evidence that (medication) does save lives, that will hopefully reduce stigmatizing and categorizing in favor of supporting individuals.”

The post U.S. Reports More Than 100,000 Overdose Deaths In One Year appeared first on High Times.